Blog - Page 4124 of 5530

TuesdayJan 20, 2009 6:17 am

Enterprise Oilfield Group, Inc. (TSX: E) Third Quarter Results; Long Term Outlook

Recently, Enterprise Oilfield Group, Inc. reported that its consolidated revenue for the three months ended September 30, 2008 totaled $8.7 million versus $8.5 million for the third quarter of the year prior. The Company had EBITDAS of $1.6 million and a net income of $0.6 million for the quarter. The management team believes the long term outlook for the company’s business segments is positive. Although continuing credit market instability will likely be unfavorably to the energy industry during 2009, Enterprise is well positioned due to the diversity of its business and strong performance of its infrastructure services division. The company…

TuesdayJan 20, 2009 5:36 am

Sector 10, Inc.’s (SECT.OB) S10Help.com Website has a Unique Focus

Sector 10, Inc. is developing S10Help.com to be a logistics tool that helps first responders and the communities in general become self-sufficient, manage response assets and increase the life saving capability and survivability of the affected. It is their aim to close the gap between private and public emergency response as well as promote a cohesive and coordinated emergency and disaster solution. Through use of the website, the company seeks to make it immediately apparent that there is a crucial need for coordinated effort, in addition to the availability of pre-deployed tools. By joining the emergency response communities and adding…

MondayJan 19, 2009 2:36 pm

January 19th CEOcast Weekly Newsletter

Companies featured in this edition of the newsletter: ACCP, ACTC, AIDO, CETG, CVM, ECOI, FMTI, GERS, GNBT, ICLK, ITUI, MNDL, MWAV The tough start to the new year didn't improve this week, as fresh concerns surrounding some prominent companies in the financial sector spurred selling which resulted in losses for all of the major indices. All told, the Dow ended the week down 317, closing down 3.7% to finish the week at 8281. The tech heavy NASDAQ fared slightly better, closing down 2.7% and ending the week at 1529. The S&P 500 and Russell 2000 both closed down as well,…

FridayJan 16, 2009 1:12 pm

HST Global, Inc. (HSTC.OB) Operates in a Recession Proof Industry

Due to the dreadful nature of cancer, HST Global, Inc. is not as affected by turbulent economic conditions. The Company’s intent is to provide World-Class treatment of cancer, as well as other life threatening diseases, regardless of the world’s economy. During the past month, HSTC.OB has been trading around $2.00. According to Small Cap Insider’s Report, the trading action is very reminiscent of a company called Health South (HLS). HLS spent most of its life on the pink sheet market in the same range, and now trades on the NYSE near $11.00. Let us hear your thoughts: HST Global, Inc.…

FridayJan 16, 2009 12:55 pm

HST Global, Inc. (HSTC.OB) has Established a Strategic Plan for Profitable Growth

The growing acceptance and demand for alternative cancer treatments around the world has perfectly positioned HST Global to launch its own brand of Cancer Treatment Centers. While the company continues to look for in-licensing pre-clinical drug candidates, this strategy will enable company to address the challenges individuals face in the treatment of cancer in the later stages. There is a growing population of individuals that are suffering as a result of the lack of available alternatives in treating late stage cancer. HST Global, Inc. has been working with a number of highly visible physicians that are developing and have developed…

FridayJan 16, 2009 12:41 pm

Keep HST Global, Inc. (HSTC.OB) on Your Radar!

HST Global, Inc. is a development-stage biotechnology company committed to acquiring, developing and commercializing innovative products to enhance cancer care. The company determines to acquire proprietary rights to these products, fund their R&D, and bring the products to market. Since HST’s inception, they have focused their efforts and resources primarily on Salicinium, a clinical stage drug candidate, as well as raising capital and recruiting personnel. The company’s focus is on in-licensing and further advancing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer. Although the cost of licensing drug candidates that have…

FridayJan 16, 2009 7:09 am

Stereotaxis, Inc. (STXS) Reports Preliminary Fourth Quarter Results

Today, Stereotaxis announced that it expects revenue for its fourth quarter ended December 31, 2008 to total approximately $12 million, which is 17% greater than the revenues generated during the same quarter in 2007. Furthermore, the company stated it anticipates a net backlog of Niobe and Odyssey systems of approximately $70 million. "Our preliminary fourth quarter revenue results demonstrate that even in the current environment of constrained hospital capital equipment spending, Stereotaxis systems continue to be regarded as strategically important to the installation of electrophysiology (EP) cath labs ," said Michael P. Kaminski, Stereotaxis President and CEO. "We also are…

FridayJan 16, 2009 6:55 am

ERF Wireless, Inc. (ERFW.OB) and Schlumberger (SLB) Enter Exclusive Reseller Agreement for United States and Canada

Today before the bell, ERF Wireless, Inc. and Schlumberger announced that they have signed an exclusive agreement for delivery of wireless broadband services throughout North America. As terms of the agreement, Schlumberger will exclusively resell wireless broadband and WiMAX terrestrial communications products and services from ERF Wireless in the North American oil and gas market. "This joint contract with ERF Wireless provides Schlumberger with the ability to deliver cost effective ubiquitous communications to the oil and gas industry in the ERF Wireless coverage areas," stated Slavo Pastor, vice president, Schlumberger Information Solutions, North America. "This will increase real-time activities and…

FridayJan 16, 2009 6:50 am

RTI Biologics, Inc. (RTIX) Announces Unaudited Revenues for 2008; Projects 2009 Revenues

RTI Biologics, a company focused on providing sterile biological implants for surgeries around the world, announced that its unaudited 2008 full year revenues are $146.6 million and fourth quarter revenues are $37.3 million, both up significantly from 2007’s full year revenues of $94.2 million and fourth quarter revenues of $25.5 million. The increase in year-over-year revenues was primarily caused by the inclusion Tutogen Medical’s revenues since the completion of the merger last February. The company also also reiterated today that its outlook for 2009 full year revenues is anticipated to be between $166 million and $168 million with earnings per…

FridayJan 16, 2009 6:05 am

Placing a Value on Kraig Biocraft Laboratories, Inc. (KBLB.OB) Technology

Emerging Growth Research, LLP recently completed a 25 page research report on Kraig Biocraft Laboratories, Inc. and its Spider Silk technology. To establish a value for the “super fiber,” the research bureau evaluated the success of DuPont’s Kevlar, which currently brings in more than $5 billion a year from sales of Kevlar. After the evaluation, Emerging Growth Research concluded that Kevlar is worth approximately $8 billion. If Kraig Biocraft makes a substantial breakthrough in the laboratory and is able to further refine its technology to produce commercial amounts, the technology will be immediately worth potentially several hundred million dollars to…

Site Search

Company Search